Saskia van de Ven

496 citations

14 papers · 361 indexed · h-index 8

Co-authors: Vincent T.H.B.M. Smit Judith R. Kroep J.W.R. Nortier Tim Dekker Lonneke W. Kessels Hanneke W.M. van Laarhoven Joan B. Heijns Ayoub Charehbili
Topics: Medical Imaging Techniques and Applications (5 papers)Breast Cancer Treatment Studies (4 papers)Radiopharmaceutical Chemistry and Applications (3 papers)
Cited by: Cancer Research Oncology Pathology and Forensic Medicine
Journals: Journal of Clinical Oncology Cancer Research International Journal of Radiation Oncology*Biology*Physics
Partner nations: Netherlands Germany United States

In The Last Decade

Saskia van de Ven

14 papers receiving 356 citations

Peers

Countries citing papers authored by Saskia van de Ven

Since Specialization

Citations

This map shows the geographic impact of Saskia van de Ven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saskia van de Ven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saskia van de Ven more than expected).

Fields of papers citing papers by Saskia van de Ven

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saskia van de Ven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saskia van de Ven. The network helps show where Saskia van de Ven may publish in the future.

Co-authorship network of co-authors of Saskia van de Ven

This figure shows the co-authorship network connecting the top 25 collaborators of Saskia van de Ven. A scholar is included among the top collaborators of Saskia van de Ven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saskia van de Ven. Saskia van de Ven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac 2023 ·Frontiers in Oncology ·(unknown),(unknown),Lois A. Daamen,H.D. Heerkens,Saskia van de Ven,Stella Mook,Gert J. Meijer,I. Quintus Molenaar,Hjalmar C. van Santvoort,E.S. Paulson,(unknown),Helena M. Verkooijen,William A. Hall,Martijn Intven	8
2	Feasibility of online radial magnetic resonance imaging for adaptive radiotherapy of pancreatic tumors 2023 ·Physics and Imaging in Radiation Oncology ·(unknown),(unknown),Jonna K. van Vulpen,Saskia van de Ven,Bas W. Raaymakers,Martijn Intven,Gert J. Meijer	3
3	Clinical implementation and feasibility of long-course fractionated MR-guided chemoradiotherapy for patients with esophageal cancer: An R-IDEAL stage 1b/2a evaluation of technical innovation 2022 ·Clinical and Translational Radiation Oncology ·(unknown),(unknown),Patricia Doornaert,Martijn Intven,J J W Lagendijk,Astrid L.H.M.W. van Lier,(unknown),Saskia van de Ven,Gert J. Meijer,Stella Mook	8
4	Patient-Reported Outcomes of Oligometastatic Patients After Conventional or Stereotactic Radiation Therapy to Bone Metastases: An Analysis of the PRESENT Cohort 2020 ·International Journal of Radiation OncologyBiologyPhysics ·Saskia van de Ven,H.J.G.D. van den Bongard,(unknown),N. Kasperts,Wietse S.C. Eppinga,Max Peters,Helena M. Verkooijen,Joanne Van der Velden	21
5	Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01) 2019 ·Breast Cancer Research ·Stefanie de Groot,Hanno Pijl,Ayoub Charehbili,Saskia van de Ven,Vincent T.H.B.M. Smit,Elma Meershoek‐Klein Kranenbarg,Joan B. Heijns,L.J.C. van Warmerdam,Lonneke W. Kessels,M. Wouter Dercksen,Manon J. Pepels,Hanneke W.M. van Laarhoven,Birgit E. P. J. Vriens,Hein Putter,Marta Fiocco,Gerrit‐Jan Liefers,Jacobus J. M. van der Hoeven,J.W.R. Nortier,Judith R. Kroep	7
6	Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01) 2016 ·Breast Cancer Research ·Stefanie de Groot,(unknown),Hanneke W.M. van Laarhoven,Antien L. Mooyaart,(unknown),Saskia van de Ven,Laura G.M. Janssen,Jesse J. Swen,Vincent T.H.B.M. Smit,Joan B. Heijns,Lonneke W. Kessels,Tahar van der Straaten,Stefan Böhringer,Hans Gelderblom,Jacobus J. M. van der Hoeven,Henk‐Jan Guchelaar,Hanno Pijl,Judith R. Kroep	33
7	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy 2014 ·Molecular Cancer Therapeutics ·Wendy Onstenk,Jaco Kraan,Bianca Mostert,(unknown),Ayoub Charehbili,Vincent T.H.B.M. Smit,Judith R. Kroep,J.W.R. Nortier,Saskia van de Ven,Joan B. Heijns,Lonneke W. Kessels,Hanneke W.M. van Laarhoven,Monique M.E.M. Bos,Cornelis J.�H. van de Velde,Jan W. Gratama,Anieta M. Sieuwerts,John W.M. Martens,John A. Foekens,Stefan Sleijfer	47
8	Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01) 2014 ·Annals of Oncology ·Ayoub Charehbili,Saskia van de Ven,Vincent T.H.B.M. Smit,Elma Meershoek‐Klein Kranenbarg,N.A.T. Hamdy,Hein Putter,Joan B. Heijns,L.J.C. van Warmerdam,Lonneke W. Kessels,M. Wouter Dercksen,Manon J. Pepels,E. Maartense,Hanneke W.M. van Laarhoven,Birgit E. P. J. Vriens,Martin N.J.M. Wasser,A. Elise van Leeuwen‐Stok,Gerrit‐Jan Liefers,C.J.H. van de Velde,J. W. R. Nortier,Judith R. Kroep	31
9	Clinical and pathological response after neoadjuvant chemotherapy with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer 2013 ·European Journal of Cancer ·Ayoub Charehbili,Saskia van de Ven,Gerrit‐Jan Liefers,Vincent T.H.B.M. Smit,Martin N.J.M. Wasser,Elma Meershoek‐Klein Kranenbarg,A. Elise van Leeuwen‐Stok,Cornelis J.�H. van de Velde,J.W.R. Nortier,Judith R. Kroep	1
10	NEOZOTAC: Efficacy results from a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC)—A Dutch Breast Cancer Trialists’ Group (BOOG) study. 2013 ·Journal of Clinical Oncology ·Ayoub Charehbili,Saskia van de Ven,Gerrit‐Jan Liefers,Vincent T.H.B.M. Smit,Hein Putter,Joan B. Heijns,(unknown),Lonneke W. Kessels,Wouter Dercksen,Manon J. Pepels,E. Maartense,Hanneke W.M. van Laarhoven,Birgit E. P. J. Vriens,Martin N.J.M. Wasser,Neveen A. T. Hamdy,(unknown),Elise van Leeuwen-Stok,Cornelis J.�H. van de Velde,Judith R. Kroep,J.W.R. Nortier	4
11	A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOG) side study. 2013 ·Journal of Clinical Oncology ·Wendy Onstenk,Jaco Kraan,Ayoub Charehbili,Bianca Mostert,Vincent T.H.B.M. Smit,Judith R. Kroep,J.W.R. Nortier,Gerrit‐Jan Liefers,Saskia van de Ven,Joan B. Heijns,Lonneke W. Kessels,Hanneke W.M. van Laarhoven,Monique M.E.M. Bos,Cornelis J.�H. van de Velde,Jan‐Willem Gratama,Anieta M. Sieuwerts,John W.M. Martens,John A. Foekens,Stefan Sleijfer	3
12	Abstract PD07-06: NEO-ZOTAC: Toxicity data of a phase III randomized trial with NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid (ZA) for patients with HER2-negative large resectable or locally advanced breast cancer (BC) 2012 ·Cancer Research ·Saskia van de Ven,Gerrit‐Jan Liefers,Hein Putter,(unknown),(unknown),(unknown),(unknown),E. Maartense,(unknown),(unknown),Vincent T.H.B.M. Smit,Martin N.J.M. Wasser,(unknown),(unknown),CJH van de Velde,(unknown),Judith R. Kroep	1
13	Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer 2010 ·Cancer Treatment Reviews ·Saskia van de Ven,Vincent T.H.B.M. Smit,Tim Dekker,J.W.R. Nortier,Judith R. Kroep	175
14	Judging Amy: Automated legal assessment using OWL 2 2008 ·UvA-DARE (University of Amsterdam) ·Saskia van de Ven,Rinke Hoekstra,Joost Breuker,(unknown),(unknown)	19

About Saskia van de Ven

Saskia van de Ven is a scholar working on Cancer Research, Radiation and Oncology, having authored 14 papers that have together received 361 indexed citations. Recurring topics across this work include Medical Imaging Techniques and Applications (5 papers), Breast Cancer Treatment Studies (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). The work is most often cited by research in Cancer Research (193 citations), Oncology (242 citations) and Pathology and Forensic Medicine (68 citations). Saskia van de Ven has collaborated with scholars based in Netherlands, Germany and United States. Frequent co-authors include Vincent T.H.B.M. Smit, Judith R. Kroep, J.W.R. Nortier, Tim Dekker, Lonneke W. Kessels, Hanneke W.M. van Laarhoven, Joan B. Heijns, Ayoub Charehbili, Rinke Hoekstra and Joost Breuker. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact